ALKS
Alkermes plc.
Key Financials
Revenue
$1.5B
↓ 5.2%
Net Income
$241.7M
↓ 34.2%
Operating Income
$254.0M
↓ 39.6%
Total Assets
$2.5B
↑ 21.0%
EPS (Diluted)
$1.43
↓ 34.1%
Shareholders' Equity
$1.8B
↑ 24.2%
Cash & Equivalents
$388.6M
↑ 33.5%
Long-term Debt
$287.7M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 144 | 10/2/2026 | View on SEC |
| 8-K | 9/21/2026 | View on SEC |
| 3 | 9/18/2026 | View on SEC |
| 8-K | 9/16/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 144 | 9/3/2026 | View on SEC |
| 4 | 9/1/2026 | View on SEC |
| 144 | 9/1/2026 | View on SEC |
| 4 | 8/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALKS |
| Company Name | Alkermes plc. |
| CIK | 1520262 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 00-353-1-772-8000 |